Ota A, Bautista A N, Yadav M L, Ueda S
Department of Neurovirology, Research Institute for Microbial Diseases, Osaka University, Suita City, Japan.
Hybridoma. 1999 Apr;18(2):139-47. doi: 10.1089/hyb.1999.18.139.
It is well known that the anti-p17 antibody titer decreases with the disease progression among human immunodeficiency virus type 1 (HIV-1) carriers. We previously established several murine anti-p17 monoclonal antibodies (MAbs) to investigate the immunological role of p17, and to further characterize these MAbs, we examined the anti-p17 antibody titer in serum of a patient who was a long-term nonprogressor with hemophilia, and found that the antibody for the p17-derivative peptide from amino acid residues 30 to 52 (P30-52) cross-reacted to the third variable region of the envelope glycoprotein of HIV-1, Env V3. In the present study, we primed mice with P30-52 to establish anti-P30-52 MAbs (P30-52 MAbs), and examined their affinity and whether they suppressed the viral multiplication of HIV-1-infected MT-4 (HTLV-1-transformed CD4+ T-cell line) cells, in a TCID50 assay. At the same time, an anti-Env V3 MAb (Env V3 MAb) was also established and examined as above. The IgM-type P30-52 MAb and Env V3 MAb showed heteroclitic binding, and the IgM-type P30-52 MAb inhibited the viral multiplication. We also found that an increase of fragmented DNA of HIV-1-infected MT-4 cells co-cultured with P30-52 MAbs. Because DNA fragmentation is one of the features of programmed cell death, the viral multiplication may be suppressed by the apoptosis of HIV-1-infected MT-4 cells co-cultured with P30-52 MAbs. Though the relationship between cross-reactivity and the inhibition mechanism of multiplication of HIV-1 is unclear, P30-52 of p17 may well be a useful region of viral proteins for the development of therapeutic and vaccination strategies.
众所周知,在1型人类免疫缺陷病毒(HIV-1)携带者中,抗p17抗体滴度会随着疾病进展而降低。我们之前制备了几种鼠抗p17单克隆抗体(MAb),以研究p17的免疫作用。为了进一步表征这些MAb,我们检测了一名患有血友病的长期病情无进展患者血清中的抗p17抗体滴度,发现针对氨基酸残基30至52的p17衍生肽(P30-52)的抗体与HIV-1包膜糖蛋白的第三个可变区Env V3发生交叉反应。在本研究中,我们用P30-52免疫小鼠以制备抗P30-52 MAb(P30-52 MAb),并在半数组织培养感染剂量(TCID50)测定中检测它们的亲和力以及是否能抑制HIV-1感染的MT-4(HTLV-1转化的CD4 + T细胞系)细胞的病毒增殖。同时,还制备了一种抗Env V3 MAb(Env V3 MAb)并进行上述检测。IgM型P30-52 MAb和Env V3 MAb表现出异嗜性结合,且IgM型P30-52 MAb抑制了病毒增殖。我们还发现,与P30-52 MAb共培养的HIV-1感染的MT-4细胞的片段化DNA增加。由于DNA片段化是程序性细胞死亡之一特征,与P30-52 MAb共培养的HIV-1感染的MT-4细胞的凋亡可能会抑制病毒增殖。虽然交叉反应性与HIV-1增殖抑制机制之间的关系尚不清楚,但p17的P30-52很可能是病毒蛋白中用于开发治疗和疫苗策略的有用区域。